These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19032701)

  • 21. The Validity of the Different Versions of the Hamilton Depression Scale in Separating Remission Rates of Placebo and Antidepressants in Clinical Trials of Major Depression.
    Kyle PR; Lemming OM; Timmerby N; Søndergaard S; Andreasson K; Bech P
    J Clin Psychopharmacol; 2016 Oct; 36(5):453-6. PubMed ID: 27525966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fear of harm, a possible phenotype of pediatric bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes.
    Papolos D; Mattis S; Golshan S; Molay F
    J Affect Disord; 2009 Nov; 118(1-3):28-38. PubMed ID: 19631388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
    J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Hamilton Depression Scale (HAM-D) and the Montgomery-Åsberg Depression Scale (MADRS). A psychometric re-analysis of the European genome-based therapeutic drugs for depression study using Rasch analysis.
    Bech P; Allerup P; Larsen ER; Csillag C; Licht RW
    Psychiatry Res; 2014 Jul; 217(3):226-32. PubMed ID: 24746391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos.
    Santor DA; Debrota D; Engelhardt N; Gelwicks S
    Depress Anxiety; 2008; 25(9):774-86. PubMed ID: 17935212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
    Ostergaard SD; Bech P; Trivedi MH; Wisniewski SR; Rush AJ; Fava M
    J Affect Disord; 2014 Jul; 163():18-24. PubMed ID: 24836083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptom indicator of severity of depression in cancer patients: a comparison of the DSM-IV criteria with alternative diagnostic criteria.
    Akechi T; Ietsugu T; Sukigara M; Okamura H; Nakano T; Akizuki N; Okamura M; Shimizu K; Okuyama T; Furukawa TA; Uchitomi Y
    Gen Hosp Psychiatry; 2009; 31(3):225-32. PubMed ID: 19410101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder.
    Hung CI; Wang SJ; Liu CY
    Depress Anxiety; 2009; 26(6):583-91. PubMed ID: 19242983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-reported consumer satisfaction in mental health services: validation of a self-rating version of the UKU-Consumer Satisfaction Rating Scale.
    Ivarsson B; Malm U
    Nord J Psychiatry; 2007; 61(3):194-200. PubMed ID: 17523031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of an IVRS version of the MADRS.
    Mundt JC; Katzelnick DJ; Kennedy SH; Eisfeld BS; Bouffard BB; Greist JH
    J Psychiatr Res; 2006 Apr; 40(3):243-6. PubMed ID: 15979643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychometric analysis of the Melancholia Scale in trials with non-pharmacological augmentation of patients with therapy-resistant depression.
    Bech P; Lauritzen L; Lunde M; Unden M; Hellström LC; Csillag C; Martiny K
    Acta Neuropsychiatr; 2014 Jun; 26(3):155-60. PubMed ID: 25142191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnosis of major depression in patients with cancer: a comparative approach.
    Guo Y; Musselman DL; Manatunga AK; Gilles N; Lawson KC; Porter MR; McDaniel JS; Nemeroff CB
    Psychosomatics; 2006; 47(5):376-84. PubMed ID: 16959925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An examination of the "gold standard" diagnosis of major depression in aged-care settings.
    Davison TE; McCabe MP; Mellor D
    Am J Geriatr Psychiatry; 2009 May; 17(5):359-67. PubMed ID: 19390293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
    Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychometric properties of responses by clinicians and older adults to a 6-item Hebrew version of the Hamilton Depression Rating Scale (HAM-D6).
    Bachner YG; O'Rourke N; Goldfracht M; Bech P; Ayalon L
    BMC Psychiatry; 2013 Jan; 13():2. PubMed ID: 23281688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression.
    Furukawa TA; Akechi T; Azuma H; Okuyama T; Higuchi T
    J Clin Psychopharmacol; 2007 Oct; 27(5):531-4. PubMed ID: 17873700
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM
    Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury.
    Ashman TA; Cantor JB; Gordon WA; Spielman L; Flanagan S; Ginsberg A; Engmann C; Egan M; Ambrose F; Greenwald B
    Arch Phys Med Rehabil; 2009 May; 90(5):733-40. PubMed ID: 19406291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Ham D(6) is more homogenous and as sensitive as the Ham D(17).
    Lecrubier Y; Bech P
    Eur Psychiatry; 2007 May; 22(4):252-5. PubMed ID: 17344030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.